OPC-12759 increases proliferation of cultured rat conjunctival goblet cells

Cornea

Volumn 25, Issue 5, 2006, Pages 573-581

  Ríos, José D ^a   Shatos, Marie ^a   Urashima, Hiroki ^b   Tran, Hao ^a   Dartt, Darlene A ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Conjunctiva; Goblet cell; Proliferation; Rebamipide

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYTOKERATIN 4 ANTIBODY; CYTOKERATIN 7 ANTIBODY; LECTIN; MONOCLONAL ANTIBODY KI 67; MUCIN 5AC ANTIBODY; PROTEIN ANTIBODY; REBAMIPIDE; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG; ALANINE; ANTIOXIDANT; ANTIULCER AGENT; COLORING AGENT; CYTOKERATIN 7; DRUG DERIVATIVE; KERATIN; KI 67 ANTIGEN; MUCIN; MUCIN 5AC; QUINOLONE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ARTICLE; CELL DIVISION; CELL PROLIFERATION; COLORIMETRY; CONCENTRATION RESPONSE; CONJUNCTIVA; CONTROLLED STUDY; DRUG EFFECT; GOBLET CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SQUAMOUS CELL; ANIMAL; CELL CULTURE; CYTOCHEMISTRY; CYTOLOGY; METABOLISM; SPRAGUE DAWLEY RAT;

ALANINE; ANIMALS; ANTI-ULCER AGENTS; ANTIOXIDANTS; CELL PROLIFERATION; CELLS, CULTURED; COLORING AGENTS; CONJUNCTIVA; GOBLET CELLS; HISTOCYTOCHEMISTRY; KERATIN-7; KERATINS; KI-67 ANTIGEN; MALE; MUCINS; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33746673364     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000208819.24990.0d     Document Type: Article

References (35)

1. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
2. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol. 1999;83:390-395.
3. Arakawa T, Kobayashi K, Yoshikawa T, et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S-13S.
4. Yamasaki K, Kanbe T, Chijiwa T, et al. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987;142:23-29.
5. Ishihara K, Komuro Y, Nishiyama N, et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung. 1992;42:1462-1466.
6. Watanabe S, Wang XE, Hirose M, et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci. 1998;43:107S-112S.
7. Udagawa A, Shiota G, Ichiba M, et al. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38:141-146.
8. Sakurai K, Yamasaki K. Protective effect of rebamipide against hydrogen peroxide-induced hemorrhagic mucosal lesions in rat stomach. Jpn J Pharmacol. 1994;64:229-234.
9. Iinuma S, Naito Y, Yoshikawa T, et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci. 1998;43:35S-39S.
10. Kurokawa T, Joh T, Ikai M, et al. Rebamipide protects against oxygen radical-mediated gastric mucosal injury in rats. Dig Dis Sci. 1998;43:113S-117S.
11. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S-98S.
12. Takahashi M, Takada H, Takagi K, et al. Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl 1):126-132.
13. Murakami K, Okajima K, Uchiba M, et al. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci. 1997;42:319-325.
14. Kim JS, Kim JM, Jung HC, et al. The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins. Aliment Pharmacol Ther. 2003;18(Suppl 1):45-54.
15. Hahm KB, Kim DH, Lee KM, et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003;18(Suppl 1):24-38.
16. Fujisawa S, Urashima H, Watanabe K. Effect of OPC-12759 eye drops on the amount of mucin-like substances on the conjunctiva. Invest Ophthalmol Vis Sci. 1999;40. Abstract 2830.
17. Urashima H, Fujisawa S, Watanabe K. Effect of OPC-12759 ophthalmic suspension on the amount of mucin-like substances on the conjunctiva. Invest Ophthalmol Vis Sci. 1999;40. Abstract 2831.
18. Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23(6):613-619.
19. Shatos MA, Rios JD, Tepavcevic V, et al. Isolation, characterization, and propagation of rat conjunctival goblet cells in vitro. Invest Ophthalmol Vis Sci. 2001;42:1455-1464.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
21. Ferrari M, Fornasiero MC, Isetta AM. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods. 1990;131:165-172.
22. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188-1197.
23. Toda I, Asano-Kato N, Hori-Komai Y, et al. Ocular surface treatment before laser in situ keratomileusis in patients with severe dry eye. J Refract Surg. 2004;20:270-275.
24. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115-1120.
25. Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113-122.
26. Lagnado R, King AJ, Donald F, et al. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004;88:464-465.
27. Urashima H, Fujita K, Kitazawa S, et al. OPC-12759 increases the mucin contents of human corneal epithelial cells in vitro. Invest Ophthalmol Vis Sci. 2003;44. E-abstract 1341.
28. Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23:613-619.
29. Kanno H, Horikawa Y, Hodges RR, et al. Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am J Physiol Cell Physiol. 2003;284:C988-C998.
30. Horikawa Y, Shatos MA, Hodges RR, et al. Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2003;44:2535-2544.
31. Pai R, Tarnawski A. Signal transduction cascades triggered by EGF receptor activation: relevance to gastric injury repair and ulcer healing. Dig Dis Sci. 1998;43:14S-22S.
32. Slice LW, Hodikian R, Zhukova E. Gastrin and EGF synergistically induce cyclooxygenase-2 expression in Swiss 3T3 fibroblasts that express the CCK2 receptor. J Cell Physiol. 2003;196:454-463.
33. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-293.
34. Shao J, Evers BM, Sheng H. PGE2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem. 2004;23:23.
35. Buchanan FG, Wang D, Bargiacchi F, et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451-35457.